Document Detail


Absence of major fibrotic adverse events in hyperprolactinemic patients treated with cabergoline.
MedLine Citation:
PMID:  20071478     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Cabergoline, a dopamine agonist used to treat hyperprolactinemia, is associated with an increased risk of fibrotic adverse reactions, e.g. cardiac valvular fibrosis, pleuropulmonary, and retroperitoneal fibrosis.
OBJECTIVE: This study evaluated the prevalence and risk of fibrotic adverse reactions during cabergoline therapy in hyperprolactinemic and acromegalic patients.
DESIGN: A cross-sectional study was conducted in a University Hospital.
PATIENTS: A total of 119 patients with hyperprolactinemia and acromegaly who were on cabergoline therapy participated in the study.
METHODS: All patients were requested to undergo a cardiac assessment, pulmonary function test, chest X-ray, and blood tests as recommended by the European Medicine Agency. Matched controls were recruited to compare the prevalence of valvular regurgitation. Cardiac valvular fibrosis was evaluated by assessing valvular regurgitation and the mitral valve tenting area (MVTa). The risk of pleuropulmonary fibrosis was assessed by a pulmonary function test, a chest X-ray, and if indicated, by additional imaging studies.
RESULTS: The prevalence of clinically relevant valvular regurgitation was not significantly different between cases (11.3%) and controls (6.1%; P=0.16). The mean MVTa was 1.27+/-0.17 and 1.24+/-0.21 cm(2) respectively (P=0.54). Both valvular regurgitation and the MVTa were not related to the cumulative dose of cabergoline. A significantly decreased pulmonary function required additional imaging in seven patients. In one patient, possible early interstitial fibrotic changes were seen. Lung function impairment was not related to the cumulative cabergoline dose.
CONCLUSION: Cabergoline, typically dosed for the long-term treatment of hyperprolactinemia or acromegaly, appears not to be associated with an increased risk of fibrotic adverse events.
Authors:
M Lafeber; A M E Stades; G D Valk; M J Cramer; F Teding van Berkhout; P M J Zelissen
Related Documents :
1552088 - Echocardiographic assessment of subvalvular aortic stenosis before and after operation.
7752828 - Usefulness of coenzyme q10 in clinical cardiology: a long-term study.
18060098 - Cocaine-related acute aortic dissection: patient demographics and clinical outcomes.
15293158 - Home monitoring of patients after prosthetic valve surgery -- experimental background a...
23354238 - Which central venous catheters have the highest rate of catheter-associated deep venous...
24729268 - Urological evaluation of patients that had undergone in utero myelomeningocele closure:...
Publication Detail:
Type:  Journal Article     Date:  2010-01-13
Journal Detail:
Title:  European journal of endocrinology / European Federation of Endocrine Societies     Volume:  162     ISSN:  1479-683X     ISO Abbreviation:  Eur. J. Endocrinol.     Publication Date:  2010 Apr 
Date Detail:
Created Date:  2010-03-25     Completed Date:  2010-04-27     Revised Date:  2013-05-28    
Medline Journal Info:
Nlm Unique ID:  9423848     Medline TA:  Eur J Endocrinol     Country:  England    
Other Details:
Languages:  eng     Pagination:  667-75     Citation Subset:  IM    
Affiliation:
Department of Internal Medicine, University Medical Center Utrecht, Room Number L 00.408, PO Box 85500, 3508 GA Utrecht, The Netherlands.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Acromegaly / blood,  drug therapy*
Blood Sedimentation
C-Reactive Protein / metabolism
Creatinine / blood
Cross-Sectional Studies
Dopamine Agonists / administration & dosage*,  therapeutic use
Echocardiography
Electrocardiography
Ergolines / adverse effects*,  therapeutic use
Female
Fibrosis
Glomerular Filtration Rate
Heart Valve Diseases / blood,  chemically induced*,  pathology
Heart Valves / pathology
Humans
Hyperprolactinemia / blood,  drug therapy*
Lung / pathology
Lung Diseases / blood,  chemically induced*,  pathology
Male
Middle Aged
Respiratory Function Tests
Retroperitoneal Fibrosis / blood,  chemically induced*,  pathology
Statistics, Nonparametric
Chemical
Reg. No./Substance:
0/Dopamine Agonists; 0/Ergolines; 60-27-5/Creatinine; 9007-41-4/C-Reactive Protein; LL60K9J05T/cabergoline

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  C1-inhibitor autoantibodies in SLE.
Next Document:  Abnormal glucose tolerance in children with cystic fibrosis: the predictive role of continuous gluco...